Leukemia stem cells (LSCs) pose a significant challenge in treating acute myeloid leukemia (AML) due to their resistance to ...

In a heartfelt testament to the power of family and community, Amanda Busch, an oncology pharmacist and mother of two, shared ...

A recent study evaluates the dosing, safety, and efficacy of telaglenastat and azacytidine to treat advanced myelodysplastic ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad ...

The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute ...

The latest high-five for UAMS comes in the form of designating the Winthrop P. Rockefeller Cancer Institute as a "center of excellence" by the Myelodysplastic Syndrome Foundation for its work with ...

Glioblastoma is the most common and aggressive type of primary brain tumor, with an average survival rate of 15 months, ...

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a Notice of ...

One of two new studies found most patients doing well six years after treatment. Another study found blood cancers in 17% of ...

No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of ...

In this article, we will look at the 8 Hot Penny Stocks To Invest In According to Hedge Funds. Let’s look at where Geron ...